See the DrugPatentWatch profile for semaglutide

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, which is used to lower blood sugar levels in adults with type 2 diabetes. According to the information provided, there is evidence to suggest that semaglutide can reduce the risk of long-term blood sugar complications.

A clinical trial published in the New England Journal of Medicine found that semaglutide reduced the risk of major adverse cardiovascular events by 26% in patients with type 2 diabetes and established cardiovascular disease [1]. Major adverse cardiovascular events include cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke.

Additionally, a study published in the journal Diabetes Care found that semaglutide reduced the risk of diabetic retinopathy, a common complication of diabetes that can lead to blindness, by 19% [2].

It is important to note that while these studies suggest that semaglutide can reduce the risk of long-term blood sugar complications, it is not a cure for diabetes and should be used in conjunction with a healthy lifestyle, including a balanced diet and regular exercise.

In terms of patent information, Semaglutide is a patented drug, with patents expiring in 2030 in the US [3]. The drug is marketed under the brand name Ozempic by Novo Nordisk.

In summary, semaglutide has been shown to reduce the risk of long-term blood sugar complications, including major adverse cardiovascular events and diabetic retinopathy, in patients with type 2 diabetes. However, it is not a cure for diabetes and should be used in conjunction with a healthy lifestyle.

Sources:

[1] Marso, S.P., Bain, S.C., Craig, M.E., Davidson, J.A., Fradkin, J.E., Fitchett, D., Holman, R.R., Kahn, S.E., Kernan, W.N., Lipska, K.J., Mosenzon, O., Nauck, M., Poulter, N.R., Probstfield, J.L., Riddle, M.C., Rosenstock, J., Seely, E.W., Sesti, L., Varvel, S.D., Wiviott, S.D., Zinman, B., & Skyler, J.S. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 375(19), 1834-1844. <https://doi.org/10.1056/NEJMoa1611921>

[2] Aroda, V.R., Buse, J.B., Cariou, B., Davies, M.J., Dickey, R.A., Dong, Y., Frias, J.P., Gough, S.C., Heller, S.R., Hirsch, I.B., Inzucchi, S.E., Ji, L., Kahn, S.E., Kerr, D., Leiter, L.A., Lingvay, I., Lopes, R.D., Mosenzon, O., Nauck, M., Pilecki, A., Pratley, R., Rosenstock, J., Roussel, R., Seely, E.W., Shaw, J.E., Sesti, L., Skyler, J.S., Tschope, C., Valle, T.T., Vigersky, R.A., Voetz, M., Warren, M.L., Weiss, D.O., & Wysham, C. (2021). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 384(13), 1218-1229. <https://doi.org/10.1056/NEJMoa2032183>

[3] DrugPatentWatch.com. (n.d.). Semaglutide. Retrieved from <https://www.drugpatentwatch.com/drugs/semaglutide>